19 January 2009

PRESS RELEASE

IMPEDI MED WINS AUSTRALIAN INNOVATION SHOOT OUT IN U.S.

The 2009 Australian Innovation Showcase was a two day program in Los Angeles and Silicon Valley to highlight Australia’s world class innovation and investment potential. Companies were selected from each of six states in Australia. ImpediMed was representing Queensland in this prestigious event.

The event occurred on January 15th and ImpediMed is proud to announce that it has won the Australian Innovation Shoot Out, held as part of the sixth annual G’Day USA: Australia Week.

Held in Silicon Valley and judged by a high profile panel of major US professional investors, the Shoot Out was a rare opportunity for ImpediMed and the five other state finalists to showcase their technologies, with the winner being judged on the uniqueness of their technology and potential for success in the US market.

ImpediMed CEO, Greg Brown said that he was humbled and delighted with the win. “The win is further validation of ImpediMed’s business opportunity as judged by a panel of US investment experts who understand what it takes to succeed in the US market.

“We are proud of what ImpediMed has achieved for patients in terms of improved health outcomes for breast cancer survivors, by providing a tool that helps their clinician to prevent the progression of lymphoedema. We also understand the importance of the ground work that we have put into physician reimbursement, clinical validation, intellectual property, and regulatory strategies in building a sustainable business. To have that validated by this win is very encouraging,” said Mr Brown.

Mr Brown said that through the Innovation Shoot Out, ImpediMed has had very positive exposure to many top tier US investment funds,

“Interest in the ImpediMed investment opportunity from the US investors was very strong,” he said.

ImpediMed would like to thank Trade Queensland and the Department of Tourism, Regional Development and Industry for their assistance with preparations for the Shoot Out.

ENDS

For further information contact:

Greg Brown Impedimed CEO +61-7-3860-3700
**About ImpediMed**

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals in the clinical assessment of secondary lymphoedema of the arm in female breast cancer patients. For more information, visit [www.impedimed.com](http://www.impedimed.com).